Streetbeat News

BAYZF

Bayer AG

https://www.bayer.de/

CEO

Werner Baumann

Industry

Pharmaceutical Preparation Manufacturing

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Bayer AG's Monsanto has been ordered by a Pennsylvania jury to pay over $2.2 billion to John McKivison, a former Roundup user who claims the weedkiller caused his non-Hodgkins lymphoma. The verdict includes $250 million for compensatory losses and $2 billion in punitive damages. Bayer plans to appeal the verdict, citing strong arguments and previous successes in reducing damage awards. The company has earmarked up to $16 billion for over 100,000 Roundup cases and faces a second wave of lawsuits.

Portfolio Pulse from Vandana Singh

January 29, 2024 | 2:41 pm

Pharmaceutical giants Amgen Inc (AMGN) and Pfizer Inc (PFE) are actively seeking entry into the $100B obesity market, aiming to challenge the dominance of Novo Nordisk (NVO) and Eli Lilly (LLY). Amgen is advancing its experimental obesity drug, MariTide, in Phase 2 trials and developing AMG 786, with data expected in late 2024 and 1H 2024, respectively. Pfizer's CEO confirmed their commitment to the obesity sector. Other companies like Merck (MRK) and Altimmune (ALT) are also developing similar treatments, while Bayer (BAYRY, BAYZF) is open to partnerships to navigate the market. These drugs are being evaluated for additional health benefits beyond weight loss.

Portfolio Pulse from Vandana Singh

January 11, 2024 | 4:40 pm

Bayer AG (OTC:BAYRY) (OTC:BAYZF) won a California lawsuit regarding its Roundup weedkiller, which a plaintiff claimed caused his non-Hodgkin lymphoma. This breaks a streak of five consecutive trial losses for Bayer. The jury found insufficient evidence linking Roundup to cancer. Despite this victory, Bayer still faces over 50,000 unresolved claims. Previously, Bayer had won nine consecutive trials and settled most pending cases in 2020 for up to $9.6 billion. However, a recent ruling in November ordered Bayer to pay $332 million in damages for a similar claim.

Portfolio Pulse from Vandana Singh

December 26, 2023 | 11:58 am

ESG investing is gaining prominence as climate-related damages surge in the US. The iShares ESG Screened S&P 500 ETF (XVV) has outperformed the S&P 500 with a 28% YTD increase. BlackRock (BLK) sees ESG as a market opportunity, particularly in climate resilience. Bayer AG (BAYRY, BAYZF), FMC Corporation (FMC), and Corteva Inc (CTVA) are highlighted as Agri-Tech companies providing solutions for sustainable agriculture and climate resilience.

Portfolio Pulse from Surbhi Jain

December 19, 2023 | 1:59 pm

Bayer AG has been ordered by a Philadelphia jury to pay nearly $3.5 million in damages for its fifth consecutive loss in lawsuits over its Roundup weedkiller. The verdict includes $462,500 in compensatory damages and $3 million in punitive damages. Bayer intends to appeal the decision, maintaining that Roundup's active ingredient, glyphosate, is safe based on scientific evidence and regulatory assessments. The ongoing litigation affects Bayer's financial position and investor confidence, with a previous verdict in November reaching $1.56 billion.

Portfolio Pulse from Vandana Singh

December 06, 2023 | 5:49 pm

Bayer AG faces increasing legal pressure as the trial in Philadelphia concerning its Roundup weedkiller nears its conclusion. The company has experienced a series of legal defeats with plaintiffs claiming Roundup caused cancer. Despite these challenges, Bayer maintains that Roundup is safe and intends to continue defending its product in court. The litigation issues began after Bayer acquired Monsanto in 2018, and although many cases were settled in 2020, around 50,000 lawsuits remain. Bayer plans to appeal recent verdicts, attributing the losses to the courts allowing misleading evidence about glyphosate, Roundup's active ingredient.

Portfolio Pulse from Vandana Singh

December 04, 2023 | 6:39 pm

Bayer AG faces investor concerns after unexpected legal and trial setbacks, including a terminated anti-clotting drug trial and adverse legal rulings regarding its Roundup weed-killer. Despite these issues, Bayer's recent $5.75 billion bond issuance attracted orders over $22 billion. Investors questioned the timing of the bond issuance and sought clarity on the financial impact of these setbacks. Bayer reassured investors of its financial reserves for Roundup litigation.

Portfolio Pulse from Vandana Singh

November 24, 2023 | 5:48 pm

The Delaware Supreme Court ruled in favor of Bayer AG, stating that Bayer is not liable for lawsuits related to talc-based products acquired from Merck & Co in 2014. The court's decision relieves Bayer of responsibility for pre-acquisition product sales, including Dr. Scholl's foot powder. Despite this victory, Bayer still faces over 40,000 pending cases regarding the Roundup weedkiller, acquired through Monsanto. Recent court losses in the Roundup cases have resulted in verdicts over $500 million, contrasting with previous wins.

Portfolio Pulse from Vandana Singh

November 17, 2023 | 11:05 am

Bayer AG's CEO, Bill Anderson, announced plans to streamline operations by reducing management levels, leading to significant staff reductions. However, he dismissed the idea of splitting the conglomerate into three separate entities. Bayer's Q3 sales fell 8.3% to €10.34 billion, with a net loss of €4.57 billion compared to a profit of €546 million a year ago. The company expects a soft growth outlook and continued challenges to profitability for next year.

Portfolio Pulse from Vandana Singh

November 08, 2023 | 4:15 pm

Bayer AG (OTC: BAYRY) (OTC: BAYZF) has lost its third trial this month related to its Roundup weed killer, with a California jury ordering the company to pay $332 million in damages. The plaintiff claimed that Roundup caused his cancer. The verdict includes $7 million in compensatory damages and $325 million in punitive damages. Bayer plans to appeal the decision. The company has faced a series of legal losses related to Roundup, with verdicts of $175 million and $1.25 million in two separate trials earlier this month.

Portfolio Pulse from Vandana Singh

November 01, 2023 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.